MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2006-12-21
Last Posted Date
2013-01-01
Lead Sponsor
Pfizer
Target Recruit Count
162
Registration Number
NCT00414661
Locations
🇺🇦

Pfizer Investigational Site, Vinnitsa, Ukraine

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: CP-690,550
Other: placebo
First Posted Date
2006-12-20
Last Posted Date
2013-01-18
Lead Sponsor
Pfizer
Target Recruit Count
509
Registration Number
NCT00413660
Locations
🇹🇷

Pfizer Investigational Site, Izmir, Turkey

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
First Posted Date
2006-12-20
Last Posted Date
2018-10-30
Lead Sponsor
Pfizer
Target Recruit Count
4488
Registration Number
NCT00413699
Locations
🇺🇸

NEA Baptist Clinic, Jonesboro, Arkansas, United States

🇺🇸

Rheumatology Associates, Portland, Maine, United States

🇮🇳

Arthritis Research and Care Foundation Centre for Rheumatic Diseases, Pune, Maharashtra, India

and more 461 locations

Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Biological: IMA-638 is a biologic
First Posted Date
2006-12-12
Last Posted Date
2014-11-18
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT00410280
Locations
🇨🇦

McMaster University Medical, Hamilton, Ontario, Canada

🇨🇦

University of British Columbia, Vancouver, British Columbia, Canada

🇨🇦

Hopital Laval, Ste-Foy, Quebec, Canada

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Phase 2
Completed
Conditions
Familial Amyloid Polyneuropathy
Interventions
Drug: Placebo
Drug: Fx-1006A
First Posted Date
2006-12-08
Last Posted Date
2012-12-17
Lead Sponsor
Pfizer
Target Recruit Count
128
Registration Number
NCT00409175
Locations
🇵🇹

Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Norte, Portugal

🇺🇸

MGH Neuropathy Laboratory, Boston, Massachusetts, United States

🇦🇷

FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Buenos Aires Province, Argentina

and more 7 locations

Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

Phase 2
Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: UK-369,003
First Posted Date
2006-12-08
Last Posted Date
2010-11-23
Lead Sponsor
Pfizer
Target Recruit Count
27
Registration Number
NCT00408954
Locations
🇸🇰

Pfizer Investigational Site, Trencin, Slovakia

Study for Evaluating Different Methods of Measuring Depression Treatment Response

Not Applicable
Completed
Conditions
Depressive Disorder, Major
First Posted Date
2006-12-04
Last Posted Date
2008-08-21
Lead Sponsor
Pfizer
Target Recruit Count
165
Registration Number
NCT00406952
Locations
🇺🇸

Pfizer Investigational Site, Midvale, Utah, United States

Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

Phase 2
Completed
Conditions
Medulloblastoma
Glioma
Interventions
First Posted Date
2006-11-28
Last Posted Date
2012-04-18
Lead Sponsor
Pfizer
Target Recruit Count
83
Registration Number
NCT00404495
Locations
🇬🇧

Pfizer Investigational Site, Sutton, United Kingdom

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Phase 3
Completed
Conditions
Vasomotor Symptoms
Interventions
First Posted Date
2006-11-20
Last Posted Date
2011-10-26
Lead Sponsor
Pfizer
Target Recruit Count
500
Registration Number
NCT00401245
Locations

Pfizer Investigational Site

Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development

Not Applicable
Completed
Conditions
Healthy Subjects
Interventions
Procedure: Blood Collection
First Posted Date
2006-11-20
Last Posted Date
2018-03-19
Lead Sponsor
Pfizer
Target Recruit Count
955
Registration Number
NCT00401232
Locations
🇺🇸

Frontage Clinical Services Inc, Hackensack, New Jersey, United States

🇺🇸

SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath